The Efficacy and Safety of Crataegus Extract WS® 1442 in Patients with Heart Failure: The SPICE Trial
- 29 November 2008
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 10 (12) , 1255-1263
Abstract
Background: Crataegus preparations have been used for centuries especially in Europe. To date, no proper data on their efficacy and safety as an add-on-treatment are available. Therefore a large morbidity/mortality trial was performed. Aim: To investigate the efficacy and safety of an add-on treatment with Crataegus extract WS® 1442 in patients with congestive heart failure. Methods: In this randomised, double-blind, placebo-controlled multicenter study, adults with NYHA class II or III CHF and reduced left ventricular ejection fraction (LVEF≤35%) were included and received 900 mg/day WS® 1442 or placebo for 24 months. Primary endpoint was time until first cardiac event. Results: 2681 patients (WS® 1442: 1338; placebo: 1343) were randomised. Average time to first cardiac event was 620 days for WS® 1442 and 606 days for placebo (event rates: 27.9% and 28.9%, hazard ratio (HR): 0.95, 95% CI [0.82;1.10]; p=0.476). The trend for cardiac mortality reduction with WS® 1442 (9.7% at month 24; HR: 0.89 [0.73;1.09]) was not statistically significant (p=0.269). In the subgroup with LVEF ≥ 25%, WS® 1442 reduced sudden cardiac death by 39.7% (HR 0.59 [0.37;0.94] at month 24; p=0.025). Adverse events were comparable in both groups. Conclusions: In this study, WS® 1442 had no significant effect on the primary endpoint. WS® 1442 was safe to use in patients receiving optimal medication for heart failure. In addition, the data may indicate that WS® 1442 can potentially reduce the incidence of sudden cardiac death, at least in patients with less compromised left ventricular function.Keywords
This publication has 22 references indexed in Scilit:
- Crataegus Special Extract WS® 1442 Induces an Endothelium-Dependent, NO-mediated Vasorelaxation via eNOS-Phosphorylation at Serine 1177Cardiovascular Drugs and Therapy, 2006
- Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trialsThe American Journal of Medicine, 2003
- Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failureAmerican Heart Journal, 2002
- Clinical efficacy of Crataegus extract WS 1442 in congestive heart failure NYHA class IIPhytomedicine, 2001
- Survival and Prognosis: Investigation of Crataegus Extract WS 1442 in Congestive Heart Failure (SPICE) — Rationale, Study Design and Study ProtocolEuropean Journal of Heart Failure, 2000
- Crataegus Special Extract WS 1442 Increases Force of Contraction in Human Myocardium cAMP-IndependentlyJournal of Cardiovascular Pharmacology, 2000
- Crataegus extract prolongs action potential duration in guinea-pig papillary musclePhytomedicine, 1996
- Effect of Oral Milrinone on Mortality in Severe Chronic Heart FailureNew England Journal of Medicine, 1991
- Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group.Circulation, 1990
- Xamoterol in severe heart failureThe Lancet, 1990